Company news

Arbutus Biopharma Corporation news in 2021

Arbutus Biopharma Corporation's news releases, calls and decks from 2021, newest first.

View company

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

December 13, 2021

Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

December 12, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement

December 6, 2021

Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity

November 30, 2021

Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors

November 10, 2021

Arbutus to Participate at Jefferies London Healthcare Conference

November 9, 2021

Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®

November 9, 2021

Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 3, 2021

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

October 31, 2021

Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

October 20, 2021

Arbutus to Participate in October Investor Conferences

September 27, 2021

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

September 20, 2021

Arbutus to Participate in Upcoming Investor Conferences

September 6, 2021

Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

August 2, 2021

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

July 28, 2021

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent

July 6, 2021

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

July 5, 2021

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

June 28, 2021

Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™

June 25, 2021

Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

June 1, 2021

Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 4, 2021

Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

April 27, 2021

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

March 31, 2021

Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

March 15, 2021

Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

March 3, 2021

Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference

March 1, 2021

Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

February 25, 2021

Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

February 21, 2021

Arbutus Announces 2021 Corporate Objectives and Provides Financial Update

January 24, 2021

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

January 3, 2021

Calls in 2021

Decks in 2021